Halozyme Therapeutics, Inc.
HALO
Jodie situation report
Halozyme Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 20 directly disclosed connections are confirming.
- Revenue increased 42.2% versus the comparable filing period.
- Operating margin fell 4.5 percentage points.
- HALO's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if HALO's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind HALO
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TEVATeva Pharmaceutical Industries LimitedsupplierMay 11, 2026 ▾
“We have commercialized auto-injector products with Teva Pharmaceutical Industries, Ltd.”
PFEPfizer, Inc.partnerMay 11, 2026 ▾
“13 Table of Contents Pfizer Collaboration In December 2012, we and Pfizer entered into a collaboration and license agreement, under which Pfizer has the worldwide license to develop and commercialize products combining our rHuPH20 enzyme with Pfizer proprieta…”
Depended on by
ORKAOruka Therapeutics, Inc.partnerMay 13, 2026 ▾
“On May 1, 2026, the Company and Halozyme Hypercon, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 21 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
HALO is currently a Early Follower in the organic co-movement group Growth Stocks. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.